{"filing":{"accession_number":"0001437749-26-018586","cik":"0001001316","ticker":"TGTX","company_name":"TG THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"tgtx20260527_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1001316/000143774926018586/tgtx20260527_8k.htm"},"events":[{"id":8813,"run_id":7735,"accession_number":"0001437749-26-018586","anchor_item_number":"8.01","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"The filing discloses positive topline results from a Phase 3 clinical trial (ENHANCE trial) for BRIUMVI®, a marketed therapeutic. While technically a clinical trial result rather than financial earnings, this represents material clinical/commercial news about a key product that would affect investor assessment of the company's pipeline and commercial prospects. The press release announcement of trial results is the core disclosure, making this functionally equivalent to an earnings-type announcement in the biotech context.","company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","filing_date":"2026-05-27","form":"8-K","submitted_at":null,"items":[{"id":2015,"accession_number":"0001437749-26-018586","item_number":"8.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses positive topline results from a Phase 3 clinical trial (ENHANCE trial) for BRIUMVI®, a marketed therapeutic. While technically a clinical trial result rather than financial earnings, this represents material clinical/commercial news about a key product that would affect investor assessment of the company's pipeline and commercial prospects. The press release announcement of trial results is the core disclosure, making this functionally equivalent to an earnings-type announcement in the biotech context.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:36:42.241206+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2015,"accession_number":"0001437749-26-018586","item_number":"8.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses positive topline results from a Phase 3 clinical trial (ENHANCE trial) for BRIUMVI®, a marketed therapeutic. While technically a clinical trial result rather than financial earnings, this represents material clinical/commercial news about a key product that would affect investor assessment of the company's pipeline and commercial prospects. The press release announcement of trial results is the core disclosure, making this functionally equivalent to an earnings-type announcement in the biotech context.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:36:42.241206+00:00","company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","filing_date":"2026-05-27"}]}